ARTICLE | Clinical News

Neurocrine gains on Phase III dyskinesia data

October 9, 2015 1:29 AM UTC

Neurocrine Biosciences Inc. (NASDAQ:NBIX) gained $4.67 (12%) to $43.60 after its NBI-98854 met the primary endpoint in the Phase III Kinect 3 trial to treat tardive dyskinesia. Daily 80 mg doses of NBI-98854 significantly reduced involuntary movement at week six, reducing scores from baseline on the Abnormal Involuntary Movement Scale (AIMS) by a least squares mean of 3.1 points more than placebo in the intent-to-treat population (p<0.0001).

Next year, the company plans to submit an NDA to FDA for the selective vesicular monoamine transporter 2 (VMAT2; SCL18A2) inhibitor. ...